Ken Griffin Bolt Biotherapeutics, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bolt Biotherapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,415,728 shares of BOLT stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,415,728
Previous 2,458,958
1.76%
Holding current value
$1.79 Million
Previous $2.75 Million
22.8%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding BOLT
# of Institutions
40Shares Held
24.3MCall Options Held
0Put Options Held
0-
Vivo Capital, LLC Palo Alto, CA3.52MShares$2.61 Million0.66% of portfolio
-
Tang Capital Management LLC San Diego, CA3.42MShares$2.53 Million0.58% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.75MShares$2.04 Million0.22% of portfolio
-
Pivotal Bio Venture Partners Investment Advisor LLC San Francisco, CA1.89MShares$1.4 Million1.94% of portfolio
-
Newtyn Management, LLC New York, NY1.7MShares$1.26 Million0.51% of portfolio
About Bolt Biotherapeutics, Inc.
- Ticker BOLT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,641,500
- Market Cap $27.9M
- Description
- Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...